CD8A and acute myeloid leukemia: The results showed that CD8 CTL (enriched for cytotoxic markers GZMB, GNLY and PRF1) were significantly increased in treatment-responded AML patients (GSE198052, Supplementary Fig. 4e), suggesting that CD8+ T cells could respond to PD-1 treatment in AML.